In vivo, this may result in two different effects: firstly, the emerging inflammatory microenvironment is associated with the influx of cytotoxic T cells and T helper cells, which confer antitumor immunity and a good prognosis for patients with cancer; secondly, pro-inflammatory mediators released by cancer cells induce several molecular signalling cascades in adjacent healthy cells, including MAPK, PI3K, Nrf2 (nuclear factor erythroid 2-related factor 2), or Janus kinases/STAT, which generally promote their antioxidant activity and increase proliferation [75]. The gene discussed is NFE2L2; the disease is cancer.